Product Segment Analysis: Peripheral Vascular Disease Drug-Eluting Balloon Catheters (Largest Segment) vs Coronary Artery Disease Drug-Eluting Balloon Catheters (Fastest-Growing Segment)

The peripheral vascular disease drug-eluting balloon catheters segment dominated the drug-eluting balloon catheters market, accounting for a share of 58.62% in 2026. Its leading position is supported by the increasing clinical use of minimally invasive procedures for peripheral artery disease and the growing preference for drug-coated technologies that help reduce restenosis while preserving vessel flexibility. The segment also benefits from the rising demand for effective treatment options in complex peripheral vascular interventions, where durable clinical outcomes and shorter recovery periods are key priorities.

The coronary artery disease drug-eluting balloon catheters segment is the fastest-growing category as healthcare providers increasingly adopt vessel-preserving interventional approaches for selected coronary lesions. Advances in balloon coating technologies, expanding clinical evidence supporting drug-eluting balloons in coronary applications, and the growing emphasis on reducing permanent implant use are encouraging broader utilization. Continuous innovation in interventional cardiology and increasing adoption of minimally invasive coronary procedures are expected to further strengthen segment growth.

Material Segment Analysis: Polyurethane (Largest & Fastest-Growing Segment)

The drug-eluting balloon catheters market was led by the polyurethane segment, which held the largest share of 38.12% in 2026 while also emerging as the fastest-growing material category. Polyurethane is widely preferred because it offers an effective balance of flexibility, durability, and biocompatibility, enabling controlled drug delivery and reliable balloon performance during vascular interventions. Its compatibility with advanced catheter designs and manufacturing processes further supports its widespread adoption as demand grows for high-performance devices capable of improving procedural precision and patient outcomes.

End Use Segment Analysis: Hospitals and Clinics (Largest Segment) vs Ambulatory Surgical Centers (Fastest-Growing Segment)

Holding the largest share of the drug-eluting balloon catheters market in 2026, hospitals and clinics remained the leading end-use segment. Their dominance is driven by the availability of specialized cardiovascular care, experienced interventional teams, and advanced imaging infrastructure required for complex vascular procedures. The ability to manage high patient volumes and provide comprehensive pre- and post-procedural care further reinforces their position as the primary treatment setting.

The ambulatory surgical centers segment is witnessing the fastest growth as healthcare systems increasingly shift suitable vascular interventions toward outpatient settings. Improvements in minimally invasive techniques, shorter recovery times, and the growing preference for cost-efficient treatment environments are encouraging greater utilization of these facilities. Continued expansion of outpatient cardiovascular services is expected to support sustained demand from ambulatory surgical centers.